NIH PROTOCOL GUIDELINES FOR WOMEN/MINORITIES IN PHASE III TRIALS
NIH PROTOCOL GUIDELINES FOR WOMEN/MINORITIES IN PHASE III TRIALS would require investigators to consider the effects of Phase III trials on women and minority groups, according to guidelines announced Jan. 24 by National Institutes of Health Office of Extramural Research Acting Director Wendy Baldwin. Investigators submitting Phase III clinical trial applications must determine whether their proposed trial intervention will have "clinically important gender or race/ethnicity differences in the intervention effect," and, if so, whether women and minorities should be included in the large-scale trials.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth